Newsletter Tool

Today’s Big News

Aug 19, 2024

'We’re pretty prolific': Lilly Catalyze360 looks to connect with emerging biotechs across 'all areas'

FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses

Fiercest Women in Life Sciences 2024: Nominations open now

Fierce Biotech Layoff Tracker 2024: Ansa removes 'handful' of R&D roles; Lykos lays off 75% of staff

Walgreens, US government ink 5-year pact to improve decentralized clinical trials

Polyrizon pays $3M for license to SciSparc's preclinical cannabinoid pain therapy

Featured

'We're pretty prolific': Lilly Catalyze360 looks to connect with emerging biotechs across 'all areas'

By Fraiser Kansteiner

As Eli Lilly continues to capitalize on its trove of Mounjaro and Zepbound cash with major outside deals, the company’s early external innovation and collaboration arm, Lilly Catalyze360, is welcoming all comers into the fold.

FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses

By James Waldron

The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate that saw three fatalities on the condition that lower doses are used.

Fiercest Women in Life Sciences 2024: Nominations open now

By Andrea Park

It’s time once again to nominate the fiercest women you know in the life science industry for our annual list.

What’s Next for Biotech? Join Fierce Biotech Editors in Boston at Fierce Biotech Summit

Fierce Biotech Layoff Tracker 2024: Ansa removes 'handful' of R&D roles; Lykos lays off 75% of staff

By Gabrielle Masson,Darren Incorvaia,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

Walgreens, US government ink 5-year pact to improve decentralized clinical trials

By Gabrielle Masson

In a continuation of their unusual partnership, Walgreens and the Biomedical Advanced Research and Development Authority are joining forces again to boost innovation and access for decentralized clinical trials.

Polyrizon pays $3M for license to SciSparc's preclinical cannabinoid pain therapy

By James Waldron

Israeli biotech SciSparc has sold the license for its cannabinoid receptor type 2 agonist to its partner Polyrizon to further develop as a pain therapy.

Genmab shuffles C-Suite on commercialization, manufacturing as portfolio grows

By Angus Liu

Genmab is revamping its executive team as the Danish antibody specialist expands its commercialization efforts and looks to evolve into “a fully integrated biotech innovation powerhouse.”

FDA clears its first at-home blood test for syphilis

By Conor Hale

Developed by NOWDiagnostics, the First To Know rapid test captures antibodies in the bloodstream that can be linked to the bacteria behind the disease, delivering a result within about 15 minutes using a drop of blood from a fingerstick.

Fierce podcasts

Don’t miss an episode

The TROP2 race for supremacy

In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

What the data says about the telehealth market

A closer look at Fierce Biotech's Fierce 15

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.